메뉴 건너뛰기




Volumn 41, Issue 10, 2015, Pages 914-924

Targeting immune checkpoints: New opportunity for mesothelioma treatment?

Author keywords

Cytotoxic T lymphocyte antigen 4; Immune checkpoint; Immunotherapy; Mesothelioma; Programmed death 1

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; LYMPHOCYTE ACTIVATION GENE 3 PROTEIN; MEMBRANE PROTEIN; PROGRAMMED DEATH 1 RECEPTOR; T CELL IMMUNOGLOBULIN MUCIN 3; TUMOR MARKER; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CD223 ANTIGEN; HAVCR2 PROTEIN, HUMAN; IMMUNOLOGIC FACTOR; LEUKOCYTE ANTIGEN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2;

EID: 84958872760     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2015.09.006     Document Type: Review
Times cited : (43)

References (125)
  • 1
    • 79953326383 scopus 로고    scopus 로고
    • Malignant pleural mesothelioma: the standard of care and challenges for future management
    • May
    • van Meerbeeck JP, Scherpereel A, Surmont VF, Baas P. Malignant pleural mesothelioma: the standard of care and challenges for future management. Crit Rev Oncol Hematol 2011 May;78(2):92-111.
    • (2011) Crit Rev Oncol Hematol , vol.78 , Issue.2 , pp. 92-111
    • van Meerbeeck, J.P.1    Scherpereel, A.2    Surmont, V.F.3    Baas, P.4
  • 2
    • 34547656272 scopus 로고    scopus 로고
    • Malignant mesothelioma: global incidence and relationship with asbestos
    • Jun
    • Bianchi C, Bianchi T. Malignant mesothelioma: global incidence and relationship with asbestos. Ind Health 2007 Jun;45(3):379-87.
    • (2007) Ind Health , vol.45 , Issue.3 , pp. 379-387
    • Bianchi, C.1    Bianchi, T.2
  • 3
    • 0034577215 scopus 로고    scopus 로고
    • Malignant mesothelioma in central and Eastern Europe
    • Bianchi C, Brollo A, Ramani L, Bianchi T. Malignant mesothelioma in central and Eastern Europe. Acta Med Croat 2000;54(4-5):161-4.
    • (2000) Acta Med Croat , vol.54 , Issue.4-5 , pp. 161-164
    • Bianchi, C.1    Brollo, A.2    Ramani, L.3    Bianchi, T.4
  • 4
    • 26444458845 scopus 로고    scopus 로고
    • Advances in malignant mesothelioma
    • Oct 13
    • Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005 Oct 13;353(15):1591-603.
    • (2005) N Engl J Med , vol.353 , Issue.15 , pp. 1591-1603
    • Robinson, B.W.1    Lake, R.A.2
  • 5
    • 79958053931 scopus 로고    scopus 로고
    • Novel targeted therapies and vaccination strategies for mesothelioma
    • Jun
    • Bagia M, Nowak AK. Novel targeted therapies and vaccination strategies for mesothelioma. Curr Treat Options Oncol 2011 Jun;12(2):149-62.
    • (2011) Curr Treat Options Oncol , vol.12 , Issue.2 , pp. 149-162
    • Bagia, M.1    Nowak, A.K.2
  • 6
    • 84883050318 scopus 로고    scopus 로고
    • Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies
    • Sep
    • Robert C, Soria JC, Eggermont AM. Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies. Eur J Cancer 2013 Sep;49(14):2968-71.
    • (2013) Eur J Cancer , vol.49 , Issue.14 , pp. 2968-2971
    • Robert, C.1    Soria, J.C.2    Eggermont, A.M.3
  • 8
    • 84879759020 scopus 로고    scopus 로고
    • Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma
    • Jul 11
    • Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013 Jul 11;369(2):134-44.
    • (2013) N Engl J Med , vol.369 , Issue.2 , pp. 134-144
    • Hamid, O.1    Robert, C.2    Daud, A.3    Hodi, F.S.4    Hwu, W.J.5    Kefford, R.6
  • 9
    • 84872514622 scopus 로고    scopus 로고
    • Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody
    • Jan 15
    • Lipson EJ, Sharfman WH, Drake CG, Wollner I, Taube JM, Anders RA, et al. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res 2013 Jan 15;19(2):462-8.
    • (2013) Clin Cancer Res , vol.19 , Issue.2 , pp. 462-468
    • Lipson, E.J.1    Sharfman, W.H.2    Drake, C.G.3    Wollner, I.4    Taube, J.M.5    Anders, R.A.6
  • 11
    • 84862903106 scopus 로고    scopus 로고
    • Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
    • Jun 28
    • Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012 Jun 28;366(26):2455-65.
    • (2012) N Engl J Med , vol.366 , Issue.26 , pp. 2455-2465
    • Brahmer, J.R.1    Tykodi, S.S.2    Chow, L.Q.3    Hwu, W.J.4    Topalian, S.L.5    Hwu, P.6
  • 12
    • 84884703526 scopus 로고    scopus 로고
    • Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial
    • Oct
    • Calabro L, Morra A, Fonsatti E, Cutaia O, Amato G, Giannarelli D, et al. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol 2013 Oct;14(11):1104-11.
    • (2013) Lancet Oncol , vol.14 , Issue.11 , pp. 1104-1111
    • Calabro, L.1    Morra, A.2    Fonsatti, E.3    Cutaia, O.4    Amato, G.5    Giannarelli, D.6
  • 13
    • 0033517152 scopus 로고    scopus 로고
    • Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation
    • Aug 2
    • van EA, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999 Aug 2;190 (3):355-66.
    • (1999) J Exp Med , vol.190 , Issue.3 , pp. 355-366
    • van, E.A.1    Hurwitz, A.A.2    Allison, J.P.3
  • 14
    • 84906935302 scopus 로고    scopus 로고
    • Myeloid-derived suppressor cells and their role in CTLA-4 blockade therapy
    • Sep
    • Pico de CY, Masucci G, Hansson J, Kiessling R. Myeloid-derived suppressor cells and their role in CTLA-4 blockade therapy. Cancer Immunol Immunother 2014 Sep;63(9):977-83.
    • (2014) Cancer Immunol Immunother , vol.63 , Issue.9 , pp. 977-983
    • Pico de, C.Y.1    Masucci, G.2    Hansson, J.3    Kiessling, R.4
  • 15
    • 0034669916 scopus 로고    scopus 로고
    • Inhibition of IgG1 and IgE production by stimulation of the B cell CTLA-4 receptor
    • Nov 15
    • Pioli C, Gatta L, Ubaldi V, Doria G. Inhibition of IgG1 and IgE production by stimulation of the B cell CTLA-4 receptor. J Immunol 2000 Nov 15;165 (10):5530-6.
    • (2000) J Immunol , vol.165 , Issue.10 , pp. 5530-5536
    • Pioli, C.1    Gatta, L.2    Ubaldi, V.3    Doria, G.4
  • 16
    • 0037220271 scopus 로고    scopus 로고
    • CTLA-4 is not restricted to the lymphoid cell lineage and can function as a target molecule for apoptosis induction of leukemic cells
    • Jan 1
    • Pistillo MP, Tazzari PL, Palmisano GL, Pierri I, Bolognesi A, Ferlito F, et al. CTLA-4 is not restricted to the lymphoid cell lineage and can function as a target molecule for apoptosis induction of leukemic cells. Blood 2003 Jan 1;101(1):202-9.
    • (2003) Blood , vol.101 , Issue.1 , pp. 202-209
    • Pistillo, M.P.1    Tazzari, P.L.2    Palmisano, G.L.3    Pierri, I.4    Bolognesi, A.5    Ferlito, F.6
  • 18
    • 44349150012 scopus 로고    scopus 로고
    • Inhibitory B7-family molecules in the tumour microenvironment
    • Jun
    • Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008 Jun;8(6):467-77.
    • (2008) Nat Rev Immunol , vol.8 , Issue.6 , pp. 467-477
    • Zou, W.1    Chen, L.2
  • 19
    • 0028852073 scopus 로고
    • Cytotoxic T lymphocyteassociated molecule-4, a high-avidity receptor for CD80 and CD86, contains an intracellular localization motif in its cytoplasmic tail
    • Oct 20
    • Leung HT, Bradshaw J, Cleaveland JS, Linsley PS. Cytotoxic T lymphocyteassociated molecule-4, a high-avidity receptor for CD80 and CD86, contains an intracellular localization motif in its cytoplasmic tail. J Biol Chem 1995 Oct 20;270(42):25107-14.
    • (1995) J Biol Chem , vol.270 , Issue.42 , pp. 25107-25114
    • Leung, H.T.1    Bradshaw, J.2    Cleaveland, J.S.3    Linsley, P.S.4
  • 20
    • 0030176371 scopus 로고    scopus 로고
    • Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement
    • Jun
    • Linsley PS, Bradshaw J, Greene J, Peach R, Bennett KL, Mittler RS. Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. Immunity 1996 Jun;4(6):535-43.
    • (1996) Immunity , vol.4 , Issue.6 , pp. 535-543
    • Linsley, P.S.1    Bradshaw, J.2    Greene, J.3    Peach, R.4    Bennett, K.L.5    Mittler, R.S.6
  • 21
    • 0034776158 scopus 로고    scopus 로고
    • Regulation of surface and intracellular expression of CTLA-4 on human peripheral T cells
    • Nov
    • Wang XB, Zheng CY, Giscombe R, Lefvert AK. Regulation of surface and intracellular expression of CTLA-4 on human peripheral T cells. Scand J Immunol 2001 Nov;54(5):453-8.
    • (2001) Scand J Immunol , vol.54 , Issue.5 , pp. 453-458
    • Wang, X.B.1    Zheng, C.Y.2    Giscombe, R.3    Lefvert, A.K.4
  • 22
    • 84890933630 scopus 로고    scopus 로고
    • Update on immune checkpoint inhibitors in lung cancer
    • Jan
    • Creelan BC. Update on immune checkpoint inhibitors in lung cancer. Cancer Control 2014 Jan;21(1):80-9.
    • (2014) Cancer Control , vol.21 , Issue.1 , pp. 80-89
    • Creelan, B.C.1
  • 23
    • 84863783251 scopus 로고    scopus 로고
    • Increase of regulatory T cells in metastatic stage and CTLA-4 over expression in lymphocytes of patients with non-small cell lung cancer (NSCLC)
    • Aug
    • Erfani N, Mehrabadi SM, Ghayumi MA, Haghshenas MR, Mojtahedi Z, Ghaderi A, et al. Increase of regulatory T cells in metastatic stage and CTLA-4 over expression in lymphocytes of patients with non-small cell lung cancer (NSCLC). Lung Cancer 2012 Aug;77(2):306-11.
    • (2012) Lung Cancer , vol.77 , Issue.2 , pp. 306-311
    • Erfani, N.1    Mehrabadi, S.M.2    Ghayumi, M.A.3    Haghshenas, M.R.4    Mojtahedi, Z.5    Ghaderi, A.6
  • 24
    • 0031058008 scopus 로고    scopus 로고
    • Human ex vivo carcinoma cells produce transforming growth factor beta and thereby can inhibit lymphocyte functions in vitro
    • Jan
    • Vanky F, Nagy N, Hising C, Sjovall K, Larson B, Klein E. Human ex vivo carcinoma cells produce transforming growth factor beta and thereby can inhibit lymphocyte functions in vitro. Cancer Immunol Immunother 1997 Jan;43(6):317-23.
    • (1997) Cancer Immunol Immunother , vol.43 , Issue.6 , pp. 317-323
    • Vanky, F.1    Nagy, N.2    Hising, C.3    Sjovall, K.4    Larson, B.5    Klein, E.6
  • 26
    • 33748987908 scopus 로고    scopus 로고
    • Cancer despite immunosurveillance: immunoselection and immunosubversion
    • Oct
    • Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006 Oct;6 (10):715-27.
    • (2006) Nat Rev Immunol , vol.6 , Issue.10 , pp. 715-727
    • Zitvogel, L.1    Tesniere, A.2    Kroemer, G.3
  • 27
    • 0031054242 scopus 로고    scopus 로고
    • CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics
    • Feb 3
    • van der Merwe PA, Bodian DL, Daenke S, Linsley P, Davis SJ. CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics. J Exp Med 1997 Feb 3;185(3):393-403.
    • (1997) J Exp Med , vol.185 , Issue.3 , pp. 393-403
    • van der Merwe, P.A.1    Bodian, D.L.2    Daenke, S.3    Linsley, P.4    Davis, S.J.5
  • 29
    • 65349119978 scopus 로고    scopus 로고
    • CD28 and CTLA-4 coreceptor expression and signal transduction
    • May
    • Rudd CE, Taylor A, Schneider H. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev 2009 May;229(1):12-26.
    • (2009) Immunol Rev , vol.229 , Issue.1 , pp. 12-26
    • Rudd, C.E.1    Taylor, A.2    Schneider, H.3
  • 30
    • 84866351492 scopus 로고    scopus 로고
    • Tumour eradication and induction of memory against murine mesothelioma by combined immunotherapy
    • Sep
    • Kissick HT, Ireland DJ, Krishnan S, Madondo M, Beilharz MW. Tumour eradication and induction of memory against murine mesothelioma by combined immunotherapy. Immunol Cell Biol 2012 Sep;90(8):822-6.
    • (2012) Immunol Cell Biol , vol.90 , Issue.8 , pp. 822-826
    • Kissick, H.T.1    Ireland, D.J.2    Krishnan, S.3    Madondo, M.4    Beilharz, M.W.5
  • 31
    • 36549027289 scopus 로고    scopus 로고
    • Anti-CTLA4 antibody clinical trials in melanoma
    • Sep
    • Ribas A. Anti-CTLA4 antibody clinical trials in melanoma. Update Cancer Ther 2007 Sep;2(3):133-9.
    • (2007) Update Cancer Ther , vol.2 , Issue.3 , pp. 133-139
    • Ribas, A.1
  • 32
    • 84876810947 scopus 로고    scopus 로고
    • The engagement of CTLA-4 on primary melanoma cell lines induces antibodydependent cellular cytotoxicity and TNF-alpha production
    • Laurent S, Queirolo P, Boero S, Salvi S, Piccioli P, Boccardo S, et al. The engagement of CTLA-4 on primary melanoma cell lines induces antibodydependent cellular cytotoxicity and TNF-alpha production. J Transl Med 2013;11:108.
    • (2013) J Transl Med , vol.11 , pp. 108
    • Laurent, S.1    Queirolo, P.2    Boero, S.3    Salvi, S.4    Piccioli, P.5    Boccardo, S.6
  • 33
    • 84878936788 scopus 로고    scopus 로고
    • Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells
    • Jul
    • Selby MJ, Engelhardt JJ, Quigley M, Henning KA, Chen T, Srinivasan M, et al. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res 2013 Jul;1 (1):32-42.
    • (2013) Cancer Immunol Res , vol.1 , Issue.1 , pp. 32-42
    • Selby, M.J.1    Engelhardt, J.J.2    Quigley, M.3    Henning, K.A.4    Chen, T.5    Srinivasan, M.6
  • 34
    • 0041629528 scopus 로고    scopus 로고
    • Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma
    • Jul 15
    • Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003 Jul 15;21(14):2636-44.
    • (2003) J Clin Oncol , vol.21 , Issue.14 , pp. 2636-2644
    • Vogelzang, N.J.1    Rusthoven, J.J.2    Symanowski, J.3    Denham, C.4    Kaukel, E.5    Ruffie, P.6
  • 36
    • 84858766182 scopus 로고    scopus 로고
    • The blockade of immune checkpoints in cancer immunotherapy
    • Apr
    • Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012 Apr;12(4):252-64.
    • (2012) Nat Rev Cancer , vol.12 , Issue.4 , pp. 252-264
    • Pardoll, D.M.1
  • 39
    • 84859158384 scopus 로고    scopus 로고
    • Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
    • Apr
    • Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012 Apr;24(2):207-12.
    • (2012) Curr Opin Immunol , vol.24 , Issue.2 , pp. 207-212
    • Topalian, S.L.1    Drake, C.G.2    Pardoll, D.M.3
  • 40
    • 77953747963 scopus 로고    scopus 로고
    • The PD-1 pathway in tolerance and autoimmunity
    • Jul
    • Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 2010 Jul;236:219-42.
    • (2010) Immunol Rev , vol.236 , pp. 219-242
    • Francisco, L.M.1    Sage, P.T.2    Sharpe, A.H.3
  • 41
    • 33646367200 scopus 로고    scopus 로고
    • The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors
    • Mar
    • Ghebeh H, Mohammed S, Al-Omair A, Qattan A, Lehe C, Al-Qudaihi G, et al. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia 2006 Mar;8(3): 190-8.
    • (2006) Neoplasia , vol.8 , Issue.3 , pp. 190-198
    • Ghebeh, H.1    Mohammed, S.2    Al-Omair, A.3    Qattan, A.4    Lehe, C.5    Al-Qudaihi, G.6
  • 42
    • 33847611968 scopus 로고    scopus 로고
    • Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer
    • Feb 27
    • Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A 2007 Feb 27;104(9):3360-5.
    • (2007) Proc Natl Acad Sci U S A , vol.104 , Issue.9 , pp. 3360-3365
    • Hamanishi, J.1    Mandai, M.2    Iwasaki, M.3    Okazaki, T.4    Tanaka, Y.5    Yamaguchi, K.6
  • 43
    • 34247532726 scopus 로고    scopus 로고
    • Clinical significance and therapeutic potential of the programmed death-1 ligand/ programmed death-1 pathway in human pancreatic cancer
    • Apr 1
    • Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/ programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 2007 Apr 1;13(7):2151-7.
    • (2007) Clin Cancer Res , vol.13 , Issue.7 , pp. 2151-2157
    • Nomi, T.1    Sho, M.2    Akahori, T.3    Hamada, K.4    Kubo, A.5    Kanehiro, H.6
  • 44
    • 20244384862 scopus 로고    scopus 로고
    • Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer
    • Apr 15
    • Ohigashi Y, Sho M, Yamada Y, Tsurui Y, Hamada K, Ikeda N, et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 2005 Apr 15;11(8):2947-53.
    • (2005) Clin Cancer Res , vol.11 , Issue.8 , pp. 2947-2953
    • Ohigashi, Y.1    Sho, M.2    Yamada, Y.3    Tsurui, Y.4    Hamada, K.5    Ikeda, N.6
  • 45
    • 34447646310 scopus 로고    scopus 로고
    • Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses
    • Jul
    • Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 2007 Jul;27(1):111-22.
    • (2007) Immunity , vol.27 , Issue.1 , pp. 111-122
    • Butte, M.J.1    Keir, M.E.2    Phamduy, T.B.3    Sharpe, A.H.4    Freeman, G.J.5
  • 48
    • 29744462591 scopus 로고    scopus 로고
    • PD-L2:PD-1 involvement in T cell proliferation, cytokine production, and integrinmediated adhesion
    • Dec
    • Saunders PA, Hendrycks VR, Lidinsky WA, Woods ML. PD-L2:PD-1 involvement in T cell proliferation, cytokine production, and integrinmediated adhesion. Eur J Immunol 2005 Dec;35(12):3561-9.
    • (2005) Eur J Immunol , vol.35 , Issue.12 , pp. 3561-3569
    • Saunders, P.A.1    Hendrycks, V.R.2    Lidinsky, W.A.3    Woods, M.L.4
  • 49
    • 84890888514 scopus 로고    scopus 로고
    • Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities
    • Jan
    • Merelli B, Massi D, Cattaneo L, Mandala M. Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities. Crit Rev Oncol Hematol 2014 Jan;89(1):140-65.
    • (2014) Crit Rev Oncol Hematol , vol.89 , Issue.1 , pp. 140-165
    • Merelli, B.1    Massi, D.2    Cattaneo, L.3    Mandala, M.4
  • 50
    • 32544459770 scopus 로고    scopus 로고
    • Restoring function in exhausted CD8 T cells during chronic viral infection
    • Feb 9
    • Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006 Feb 9;439(7077):682-7.
    • (2006) Nature , vol.439 , Issue.7077 , pp. 682-687
    • Barber, D.L.1    Wherry, E.J.2    Masopust, D.3    Zhu, B.4    Allison, J.P.5    Sharpe, A.H.6
  • 52
    • 18544380239 scopus 로고    scopus 로고
    • Tumorassociated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion
    • Aug
    • Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumorassociated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002 Aug;8(8):793-800.
    • (2002) Nat Med , vol.8 , Issue.8 , pp. 793-800
    • Dong, H.1    Strome, S.E.2    Salomao, D.R.3    Tamura, H.4    Hirano, F.5    Flies, D.B.6
  • 53
    • 33645736792 scopus 로고    scopus 로고
    • Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up
    • Apr 1
    • Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 2006 Apr 1;66(7):3381-5.
    • (2006) Cancer Res , vol.66 , Issue.7 , pp. 3381-3385
    • Thompson, R.H.1    Kuntz, S.M.2    Leibovich, B.C.3    Dong, H.4    Lohse, C.M.5    Webster, W.S.6
  • 54
    • 33745197352 scopus 로고    scopus 로고
    • Blockade of PDL1 (B7-H1) augments human tumor-specific T cell responses in vitro
    • Jul 15
    • Blank C, Kuball J, Voelkl S, Wiendl H, Becker B, Walter B, et al. Blockade of PDL1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer 2006 Jul 15;119(2):317-27.
    • (2006) Int J Cancer , vol.119 , Issue.2 , pp. 317-327
    • Blank, C.1    Kuball, J.2    Voelkl, S.3    Wiendl, H.4    Becker, B.5    Walter, B.6
  • 55
    • 70349562580 scopus 로고    scopus 로고
    • Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression
    • Aug 20
    • Mumprecht S, Schurch C, Schwaller J, Solenthaler M, Ochsenbein AF. Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. Blood 2009 Aug 20;114 (8):1528-36.
    • (2009) Blood , vol.114 , Issue.8 , pp. 1528-1536
    • Mumprecht, S.1    Schurch, C.2    Schwaller, J.3    Solenthaler, M.4    Ochsenbein, A.F.5
  • 56
    • 70349561448 scopus 로고    scopus 로고
    • PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model
    • Aug 20
    • Zhang L, Gajewski TF, Kline J. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood 2009 Aug 20;114(8):1545-52.
    • (2009) Blood , vol.114 , Issue.8 , pp. 1545-1552
    • Zhang, L.1    Gajewski, T.F.2    Kline, J.3
  • 57
    • 84925529257 scopus 로고    scopus 로고
    • Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
    • Jan
    • Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med 2015 Jan;21(1):24-33.
    • (2015) Trends Mol Med , vol.21 , Issue.1 , pp. 24-33
    • Ohaegbulam, K.C.1    Assal, A.2    Lazar-Molnar, E.3    Yao, Y.4    Zang, X.5
  • 58
    • 73949088551 scopus 로고    scopus 로고
    • PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
    • Dec 21
    • Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 2009 Dec 21;206(13):3015-29.
    • (2009) J Exp Med , vol.206 , Issue.13 , pp. 3015-3029
    • Francisco, L.M.1    Salinas, V.H.2    Brown, K.E.3    Vanguri, V.K.4    Freeman, G.J.5    Kuchroo, V.K.6
  • 59
    • 45549098562 scopus 로고    scopus 로고
    • T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR
    • Jun 3
    • Sauer S, Bruno L, Hertweck A, Finlay D, Leleu M, Spivakov M, et al. T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc Natl Acad Sci U S A 2008 Jun 3;105(22):7797-802.
    • (2008) Proc Natl Acad Sci U S A , vol.105 , Issue.22 , pp. 7797-7802
    • Sauer, S.1    Bruno, L.2    Hertweck, A.3    Finlay, D.4    Leleu, M.5    Spivakov, M.6
  • 60
    • 84923078390 scopus 로고    scopus 로고
    • MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
    • Nov 27
    • Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014 Nov 27;515(7528):558-62.
    • (2014) Nature , vol.515 , Issue.7528 , pp. 558-562
    • Powles, T.1    Eder, J.P.2    Fine, G.D.3    Braiteh, F.S.4    Loriot, Y.5    Cruz, C.6
  • 61
    • 36048963838 scopus 로고    scopus 로고
    • LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems
    • Nov
    • Grosso JF, Kelleher CC, Harris TJ, Maris CH, Hipkiss EL, De MA, et al. LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Invest 2007 Nov;117(11):3383-92.
    • (2007) J Clin Invest , vol.117 , Issue.11 , pp. 3383-3392
    • Grosso, J.F.1    Kelleher, C.C.2    Harris, T.J.3    Maris, C.H.4    Hipkiss, E.L.5    De, M.A.6
  • 62
    • 77957744369 scopus 로고    scopus 로고
    • Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
    • Sep 27
    • Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 2010 Sep 27;207(10):2187-94.
    • (2010) J Exp Med , vol.207 , Issue.10 , pp. 2187-2194
    • Sakuishi, K.1    Apetoh, L.2    Sullivan, J.M.3    Blazar, B.R.4    Kuchroo, V.K.5    Anderson, A.C.6
  • 63
    • 77957723967 scopus 로고    scopus 로고
    • Upregulation of Tim-3 and PD-1 expression is associated with tumor antigenspecific CD8+ T cell dysfunction in melanoma patients
    • Sep 27
    • Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigenspecific CD8+ T cell dysfunction in melanoma patients. J Exp Med 2010 Sep 27;207(10):2175-86.
    • (2010) J Exp Med , vol.207 , Issue.10 , pp. 2175-2186
    • Fourcade, J.1    Sun, Z.2    Benallaoua, M.3    Guillaume, P.4    Luescher, I.F.5    Sander, C.6
  • 64
    • 67650966949 scopus 로고    scopus 로고
    • Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma
    • Aug
    • Gehring AJ, Ho ZZ, Tan AT, Aung MO, Lee KH, Tan KC, et al. Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma. Gastroenterology 2009 Aug;137(2):682-90.
    • (2009) Gastroenterology , vol.137 , Issue.2 , pp. 682-690
    • Gehring, A.J.1    Ho, Z.Z.2    Tan, A.T.3    Aung, M.O.4    Lee, K.H.5    Tan, K.C.6
  • 65
    • 54449088740 scopus 로고    scopus 로고
    • Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 blockade
    • Sep 30
    • Blackburn SD, Shin H, Freeman GJ, Wherry EJ. Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 blockade. Proc Natl Acad Sci U S A 2008 Sep 30;105(39):15016-21.
    • (2008) Proc Natl Acad Sci U S A , vol.105 , Issue.39 , pp. 15016-15021
    • Blackburn, S.D.1    Shin, H.2    Freeman, G.J.3    Wherry, E.J.4
  • 66
    • 66949111877 scopus 로고    scopus 로고
    • PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients
    • May 1
    • Fourcade J, Kudela P, Sun Z, Shen H, Land SR, Lenzner D, et al. PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol 2009 May 1;182(9):5240-9.
    • (2009) J Immunol , vol.182 , Issue.9 , pp. 5240-5249
    • Fourcade, J.1    Kudela, P.2    Sun, Z.3    Shen, H.4    Land, S.R.5    Lenzner, D.6
  • 67
    • 79955530122 scopus 로고    scopus 로고
    • MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis
    • May 1
    • Hemon P, Jean-Louis F, Ramgolam K, Brignone C, Viguier M, Bachelez H, et al. MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis. J Immunol 2011 May 1;186(9):5173-83.
    • (2011) J Immunol , vol.186 , Issue.9 , pp. 5173-5183
    • Hemon, P.1    Jean-Louis, F.2    Ramgolam, K.3    Brignone, C.4    Viguier, M.5    Bachelez, H.6
  • 68
    • 0030902983 scopus 로고    scopus 로고
    • Characterization of the major histocompatibility complex class II binding site on LAG-3 protein
    • May 27
    • Huard B, Mastrangeli R, Prigent P, Bruniquel D, Donini S, El-Tayar N, et al. Characterization of the major histocompatibility complex class II binding site on LAG-3 protein. Proc Natl Acad Sci U S A 1997 May 27;94(11):5744-9.
    • (1997) Proc Natl Acad Sci U S A , vol.94 , Issue.11 , pp. 5744-5749
    • Huard, B.1    Mastrangeli, R.2    Prigent, P.3    Bruniquel, D.4    Donini, S.5    El-Tayar, N.6
  • 70
    • 2142815854 scopus 로고    scopus 로고
    • Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo
    • May 1
    • Workman CJ, Cauley LS, Kim IJ, Blackman MA, Woodland DL, Vignali DA. Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo. J Immunol 2004 May 1;172(9):5450-5.
    • (2004) J Immunol , vol.172 , Issue.9 , pp. 5450-5455
    • Workman, C.J.1    Cauley, L.S.2    Kim, I.J.3    Blackman, M.A.4    Woodland, D.L.5    Vignali, D.A.6
  • 71
    • 19544374904 scopus 로고    scopus 로고
    • The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells
    • Jun
    • Macon-Lemaitre L, Triebel F. The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells. Immunology 2005 Jun;115(2):170-8.
    • (2005) Immunology , vol.115 , Issue.2 , pp. 170-178
    • Macon-Lemaitre, L.1    Triebel, F.2
  • 72
    • 11844269957 scopus 로고    scopus 로고
    • Negative regulation of T cell homeostasis by lymphocyte activation gene-3 (CD223)
    • Jan 15
    • Workman CJ, Vignali DA. Negative regulation of T cell homeostasis by lymphocyte activation gene-3 (CD223). J Immunol 2005 Jan 15;174 (2):688-95.
    • (2005) J Immunol , vol.174 , Issue.2 , pp. 688-695
    • Workman, C.J.1    Vignali, D.A.2
  • 73
    • 84879085032 scopus 로고    scopus 로고
    • A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma
    • Jun
    • Wang-Gillam A, Plambeck-Suess S, Goedegebuure P, Simon PO, Mitchem JB, Hornick JR, et al. A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma. Invest New Drugs 2013 Jun;31(3):707-13.
    • (2013) Invest New Drugs , vol.31 , Issue.3 , pp. 707-713
    • Wang-Gillam, A.1    Plambeck-Suess, S.2    Goedegebuure, P.3    Simon, P.O.4    Mitchem, J.B.5    Hornick, J.R.6
  • 74
    • 70349669259 scopus 로고    scopus 로고
    • A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma
    • Oct 1
    • Brignone C, Escudier B, Grygar C, Marcu M, Triebel F. A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma. Clin Cancer Res 2009 Oct 1;15(19):6225-31.
    • (2009) Clin Cancer Res , vol.15 , Issue.19 , pp. 6225-6231
    • Brignone, C.1    Escudier, B.2    Grygar, C.3    Marcu, M.4    Triebel, F.5
  • 75
    • 0037203867 scopus 로고    scopus 로고
    • Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease
    • Jan 31
    • Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, Chernova T, et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 2002 Jan 31;415(6871): 536-41.
    • (2002) Nature , vol.415 , Issue.6871 , pp. 536-541
    • Monney, L.1    Sabatos, C.A.2    Gaglia, J.L.3    Ryu, A.4    Waldner, H.5    Chernova, T.6
  • 76
    • 30044434075 scopus 로고    scopus 로고
    • The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity
    • Dec
    • Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 2005 Dec;6(12):1245-52.
    • (2005) Nat Immunol , vol.6 , Issue.12 , pp. 1245-1252
    • Zhu, C.1    Anderson, A.C.2    Schubart, A.3    Xiong, H.4    Imitola, J.5    Khoury, S.J.6
  • 77
    • 36248967595 scopus 로고    scopus 로고
    • Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells
    • Nov 16
    • Anderson AC, Anderson DE, Bregoli L, Hastings WD, Kassam N, Lei C, et al. Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science 2007 Nov 16;318(5853):1141-3.
    • (2007) Science , vol.318 , Issue.5853 , pp. 1141-1143
    • Anderson, A.C.1    Anderson, D.E.2    Bregoli, L.3    Hastings, W.D.4    Kassam, N.5    Lei, C.6
  • 78
    • 79956103042 scopus 로고    scopus 로고
    • Anti-TIM3 antibody promotes T cell IFN-gamma-mediated antitumor immunity and suppresses established tumors
    • May 15
    • Ngiow SF, von SB, Akiba H, Yagita H, Teng MW, Smyth MJ. Anti-TIM3 antibody promotes T cell IFN-gamma-mediated antitumor immunity and suppresses established tumors. Cancer Res 2011 May 15;71(10):3540-51.
    • (2011) Cancer Res , vol.71 , Issue.10 , pp. 3540-3551
    • Ngiow, S.F.1    von, S.B.2    Akiba, H.3    Yagita, H.4    Teng, M.W.5    Smyth, M.J.6
  • 79
    • 79955977180 scopus 로고    scopus 로고
    • Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia
    • Apr 28
    • Zhou Q, Munger ME, Veenstra RG, Weigel BJ, Hirashima M, Munn DH, et al. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood 2011 Apr 28;117(17):4501-10.
    • (2011) Blood , vol.117 , Issue.17 , pp. 4501-4510
    • Zhou, Q.1    Munger, M.E.2    Veenstra, R.G.3    Weigel, B.J.4    Hirashima, M.5    Munn, D.H.6
  • 80
    • 59849116262 scopus 로고    scopus 로고
    • Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients
    • Oct
    • Fourcade J, Kudela P, Andrade Filho PA, Janjic B, Land SR, Sander C, et al. Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients. J Immunother 2008 Oct;31(8):781-91.
    • (2008) J Immunother , vol.31 , Issue.8 , pp. 781-791
    • Fourcade, J.1    Kudela, P.2    Andrade Filho, P.A.3    Janjic, B.4    Land, S.R.5    Sander, C.6
  • 81
    • 49649114804 scopus 로고    scopus 로고
    • Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies
    • May 15
    • Berger R, Rotem-Yehudar R, Slama G, Landes S, Kneller A, Leiba M, et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 2008 May 15;14(10):3044-51.
    • (2008) Clin Cancer Res , vol.14 , Issue.10 , pp. 3044-3051
    • Berger, R.1    Rotem-Yehudar, R.2    Slama, G.3    Landes, S.4    Kneller, A.5    Leiba, M.6
  • 82
    • 77954899030 scopus 로고    scopus 로고
    • Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates
    • Jul 1
    • Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010 Jul 1;28(19):3167-75.
    • (2010) J Clin Oncol , vol.28 , Issue.19 , pp. 3167-3175
    • Brahmer, J.R.1    Drake, C.G.2    Wollner, I.3    Powderly, J.D.4    Picus, J.5    Sharfman, W.H.6
  • 83
    • 84936791837 scopus 로고    scopus 로고
    • Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer
    • Jul 9
    • Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015 Jul 9;373(2):123-35.
    • (2015) N Engl J Med , vol.373 , Issue.2 , pp. 123-135
    • Brahmer, J.1    Reckamp, K.L.2    Baas, P.3    Crino, L.4    Eberhardt, W.E.5    Poddubskaya, E.6
  • 84
    • 84888352977 scopus 로고    scopus 로고
    • Clinical and pharmacodynamic (PD) results of a phase I trial with AMP-224 (B7-DC Fc) that binds to the PD-1 receptor
    • Infante JR, Powderly JD, Burris HA, Kittaneh M, Houston Grice J, Smother JF, et al. Clinical and pharmacodynamic (PD) results of a phase I trial with AMP-224 (B7-DC Fc) that binds to the PD-1 receptor. J Clin Oncol 2013;31.
    • (2013) J Clin Oncol , pp. 31
    • Infante, J.R.1    Powderly, J.D.2    Burris, H.A.3    Kittaneh, M.4    Houston Grice, J.5    Smother, J.F.6
  • 85
    • 37549040613 scopus 로고    scopus 로고
    • Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
    • Dec 27
    • Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007 Dec 27;357(26):2666-76.
    • (2007) N Engl J Med , vol.357 , Issue.26 , pp. 2666-2676
    • Miller, K.1    Wang, M.2    Gralow, J.3    Dickler, M.4    Cobleigh, M.5    Perez, E.A.6
  • 86
    • 77955487541 scopus 로고    scopus 로고
    • First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity
    • Brignone C, Gutierrez M, Mefti F, Brain E, Jarcau R, Cvitkovic F, et al. First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity. J Transl Med 2010;8:71.
    • (2010) J Transl Med , vol.8 , pp. 71
    • Brignone, C.1    Gutierrez, M.2    Mefti, F.3    Brain, E.4    Jarcau, R.5    Cvitkovic, F.6
  • 87
    • 77950283280 scopus 로고    scopus 로고
    • Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma
    • Apr 1
    • Hino R, Kabashima K, Kato Y, Yagi H, Nakamura M, Honjo T, et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 2010 Apr 1;116(7):1757-66.
    • (2010) Cancer , vol.116 , Issue.7 , pp. 1757-1766
    • Hino, R.1    Kabashima, K.2    Kato, Y.3    Yagi, H.4    Nakamura, M.5    Honjo, T.6
  • 88
    • 79955518331 scopus 로고    scopus 로고
    • Overall survival and PD-L1 expression in metastasized malignant melanoma
    • May 15
    • Gadiot J, Hooijkaas AI, Kaiser AD, van TH, van BH, Blank C. Overall survival and PD-L1 expression in metastasized malignant melanoma. Cancer 2011 May 15;117(10):2192-201.
    • (2011) Cancer , vol.117 , Issue.10 , pp. 2192-2201
    • Gadiot, J.1    Hooijkaas, A.I.2    Kaiser, A.D.3    van, T.H.4    van, B.H.5    Blank, C.6
  • 90
    • 84873666114 scopus 로고    scopus 로고
    • Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-yearfollow- up study
    • Nov
    • Chen YB, Mu CY, Huang JA. Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-yearfollow- up study. Tumori 2012 Nov;98(6):751-5.
    • (2012) Tumori , vol.98 , Issue.6 , pp. 751-755
    • Chen, Y.B.1    Mu, C.Y.2    Huang, J.A.3
  • 91
    • 34250177269 scopus 로고    scopus 로고
    • PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma
    • Mar 15
    • Thompson RH, Dong H, Lohse CM, Leibovich BC, Blute ML, Cheville JC, et al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res 2007 Mar 15;13(6):1757-61.
    • (2007) Clin Cancer Res , vol.13 , Issue.6 , pp. 1757-1761
    • Thompson, R.H.1    Dong, H.2    Lohse, C.M.3    Leibovich, B.C.4    Blute, M.L.5    Cheville, J.C.6
  • 93
    • 84942890493 scopus 로고    scopus 로고
    • Noninvasive imaging of tumor PD-L1 expression using radiolabeled anti-PD-L1 antibodies
    • Jul 15
    • Heskamp S, Hobo W, Molkenboer-Kuenen JD, Olive D, Oyen WJ, Dolstra H, et al. Noninvasive imaging of tumor PD-L1 expression using radiolabeled anti-PD-L1 antibodies. Cancer Res 2015 Jul 15;75(14):2928-36.
    • (2015) Cancer Res , vol.75 , Issue.14 , pp. 2928-2936
    • Heskamp, S.1    Hobo, W.2    Molkenboer-Kuenen, J.D.3    Olive, D.4    Oyen, W.J.5    Dolstra, H.6
  • 95
    • 84861453989 scopus 로고    scopus 로고
    • Immunity and malignant mesothelioma: from mesothelial cell damage to tumor development and immune response-based therapies
    • Sep 1
    • Izzi V, Masuelli L, Tresoldi I, Foti C, Modesti A, Bei R. Immunity and malignant mesothelioma: from mesothelial cell damage to tumor development and immune response-based therapies. Cancer Lett 2012 Sep 1;322(1):18-34.
    • (2012) Cancer Lett , vol.322 , Issue.1 , pp. 18-34
    • Izzi, V.1    Masuelli, L.2    Tresoldi, I.3    Foti, C.4    Modesti, A.5    Bei, R.6
  • 96
    • 77955558708 scopus 로고    scopus 로고
    • CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection
    • Oct
    • Yamada N, Oizumi S, Kikuchi E, Shinagawa N, Konishi-Sakakibara J, Ishimine A, et al. CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection. Cancer Immunol Immunother 2010 Oct;59(10):1543-9.
    • (2010) Cancer Immunol Immunother , vol.59 , Issue.10 , pp. 1543-1549
    • Yamada, N.1    Oizumi, S.2    Kikuchi, E.3    Shinagawa, N.4    Konishi-Sakakibara, J.5    Ishimine, A.6
  • 97
    • 0019994040 scopus 로고
    • Lymphocytic infiltration of pleural mesothelioma and its significance for survival
    • Leigh AR, Webster I. Lymphocytic infiltration of pleural mesothelioma and its significance for survival. S Afr Med J 1982;61:1007-9.
    • (1982) S Afr Med J , vol.61 , pp. 1007-1009
    • Leigh, A.R.1    Webster, I.2
  • 98
    • 40949119354 scopus 로고    scopus 로고
    • Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma
    • Apr
    • Anraku M, Cunningham KS, Yun Z, Tsao MS, Zhang L, Keshavjee S, et al. Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2008 Apr;135(4):823-9.
    • (2008) J Thorac Cardiovasc Surg , vol.135 , Issue.4 , pp. 823-829
    • Anraku, M.1    Cunningham, K.S.2    Yun, Z.3    Tsao, M.S.4    Zhang, L.5    Keshavjee, S.6
  • 99
    • 0036704354 scopus 로고    scopus 로고
    • No relationship between tumour infiltrating lymphocytes and overall survival is seen in malignant mesothelioma of the pleura
    • Aug
    • Mudhar HS, Fisher PM, Wallace WA. No relationship between tumour infiltrating lymphocytes and overall survival is seen in malignant mesothelioma of the pleura. Eur J Surg Oncol 2002 Aug;28(5):564-5.
    • (2002) Eur J Surg Oncol , vol.28 , Issue.5 , pp. 564-565
    • Mudhar, H.S.1    Fisher, P.M.2    Wallace, W.A.3
  • 100
    • 84876522514 scopus 로고    scopus 로고
    • Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity
    • Lesterhuis WJ, Salmons J, Nowak AK, Rozali EN, Khong A, Dick IM, et al. Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity. PLoS One 2013;8(4):e61895.
    • (2013) PLoS One , vol.8 , Issue.4
    • Lesterhuis, W.J.1    Salmons, J.2    Nowak, A.K.3    Rozali, E.N.4    Khong, A.5    Dick, I.M.6
  • 101
    • 84864886189 scopus 로고    scopus 로고
    • CTLA-4 blockade expands infiltrating T cells and inhibits cancer cell repopulation during the intervals of chemotherapy in murine mesothelioma
    • Aug
    • Wu L, Yun Z, Tagawa T, Rey-McIntyre K, de PM. CTLA-4 blockade expands infiltrating T cells and inhibits cancer cell repopulation during the intervals of chemotherapy in murine mesothelioma. Mol Cancer Ther 2012 Aug;11(8):1809-19.
    • (2012) Mol Cancer Ther , vol.11 , Issue.8 , pp. 1809-1819
    • Wu, L.1    Yun, Z.2    Tagawa, T.3    Rey-McIntyre, K.4    de, P.M.5
  • 102
    • 84856577906 scopus 로고    scopus 로고
    • Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey
    • Mar
    • Zucali PA, Simonelli M, Michetti G, Tiseo M, Ceresoli GL, Collova E, et al. Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey. Lung Cancer 2012 Mar;75(3):360-7.
    • (2012) Lung Cancer , vol.75 , Issue.3 , pp. 360-367
    • Zucali, P.A.1    Simonelli, M.2    Michetti, G.3    Tiseo, M.4    Ceresoli, G.L.5    Collova, E.6
  • 103
    • 84907651087 scopus 로고    scopus 로고
    • A phase 2 single-arm study with tremelimumab at an optimized dosing schedule in second-line mesothelioma patients
    • Calabro L, Morra A, Fonsatti E, Cuataia O, Fazio C, Danielli R, et al. A phase 2 single-arm study with tremelimumab at an optimized dosing schedule in second-line mesothelioma patients. J Clin Oncol 2014;32.
    • (2014) J Clin Oncol , pp. 32
    • Calabro, L.1    Morra, A.2    Fonsatti, E.3    Cuataia, O.4    Fazio, C.5    Danielli, R.6
  • 104
    • 84977745299 scopus 로고    scopus 로고
    • A randomized, double-blind study comparing tremelimumab to placebo in second and third line treatment of subjects with unresectable pleural or peritoneal mesothelioma
    • Kindler HL, Di Pietro A, Robbins PB, Hong S, Shalabi A, Ibrahim R, et al. A randomized, double-blind study comparing tremelimumab to placebo in second and third line treatment of subjects with unresectable pleural or peritoneal mesothelioma. J Thorac Oncol 2013;8.
    • (2013) J Thorac Oncol , pp. 8
    • Kindler, H.L.1    Di Pietro, A.2    Robbins, P.B.3    Hong, S.4    Shalabi, A.5    Ibrahim, R.6
  • 105
    • 84907674237 scopus 로고    scopus 로고
    • Randomized, double-blind, placebo-controlled study of tremelimumab for second and third-line treatment of unresectable pleural or peritoneal mesothelioma
    • Maio M, Scherpereel A, Di Pietro A, Vasey P, Tsao AS, Calabrò L, et al. Randomized, double-blind, placebo-controlled study of tremelimumab for second and third-line treatment of unresectable pleural or peritoneal mesothelioma. J Clin Oncol 2014;32.
    • (2014) J Clin Oncol , pp. 32
    • Maio, M.1    Scherpereel, A.2    Di Pietro, A.3    Vasey, P.4    Tsao, A.S.5    Calabrò, L.6
  • 106
    • 84902522051 scopus 로고    scopus 로고
    • B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis
    • Jul
    • MansfieldAS,RodenAC,Peikert T,SheininYM,HarringtonSM,KrcoCJ, et al. B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. J Thorac Oncol 2014 Jul;9(7):1036-40.
    • (2014) J Thorac Oncol , vol.9 , Issue.7 , pp. 1036-1040
    • Mansfield, A.S.1    Roden, A.C.2    Peikert, T.3    Sheinin, Y.M.4    Harrington, S.M.5    Krco, C.J.6
  • 107
    • 84977740936 scopus 로고    scopus 로고
    • Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)
    • Cedres S, Ponce Aix S, Zugazagoitia J, Anguita A, Sansano I, Navarro A, et al. Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). Ann Oncol 2014;25(5).
    • (2014) Ann Oncol , vol.25 , Issue.5
    • Cedres, S.1    Ponce Aix, S.2    Zugazagoitia, J.3    Anguita, A.4    Sansano, I.5    Navarro, A.6
  • 108
    • 84925004185 scopus 로고    scopus 로고
    • Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)
    • Cedres S, Ponce-Aix S, Zugazagoitia J, Sansano I, Enguita A, Navarro-Mendivil A, et al. Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). PLoS One 2015;10(3):e0121071.
    • (2015) PLoS One , vol.10 , Issue.3
    • Cedres, S.1    Ponce-Aix, S.2    Zugazagoitia, J.3    Sansano, I.4    Enguita, A.5    Navarro-Mendivil, A.6
  • 109
    • 85029889678 scopus 로고    scopus 로고
    • PD-L1 expression in malignant mesothelioma: an immunohistochemical analysis of 33 cases
    • Cowan ML, Forde PM, Taube JM, Illei PB. PD-L1 expression in malignant mesothelioma: an immunohistochemical analysis of 33 cases. Lab Invest 2014;94.
    • (2014) Lab Invest , pp. 94
    • Cowan, M.L.1    Forde, P.M.2    Taube, J.M.3    Illei, P.B.4
  • 111
    • 84890814629 scopus 로고    scopus 로고
    • Breakthrough of the year 2013. Cancer immunotherapy
    • Dec 20
    • Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science 2013 Dec 20;342(6165):1432-3.
    • (2013) Science , vol.342 , Issue.6165 , pp. 1432-1433
    • Couzin-Frankel, J.1
  • 112
    • 85016910370 scopus 로고    scopus 로고
    • Integrating immune checkpoint blockade with anti-neo/mutated antigens reactivity to increase the clinical outcome of immunotherapy
    • Parmiani Giorgio, Macalli Cristina, Maio Michele. Integrating immune checkpoint blockade with anti-neo/mutated antigens reactivity to increase the clinical outcome of immunotherapy. Vaccines 2015;3(2):420-8.
    • (2015) Vaccines , vol.3 , Issue.2 , pp. 420-428
    • Giorgio, P.1    Cristina, M.2    Maio, Michele3
  • 114
    • 77749279776 scopus 로고    scopus 로고
    • PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
    • Mar 2
    • Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A 2010 Mar 2;107 (9):4275-80.
    • (2010) Proc Natl Acad Sci U S A , vol.107 , Issue.9 , pp. 4275-4280
    • Curran, M.A.1    Montalvo, W.2    Yagita, H.3    Allison, J.P.4
  • 116
    • 84985921065 scopus 로고    scopus 로고
    • Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: interim phase I results
    • Scott JA, Scott N, Gettinger N, Quan Man Chow L, Juergens RA, Borghaei H, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: interim phase I results. J Clin Oncol 2014;32(5s).
    • (2014) J Clin Oncol , vol.32 , Issue.5
    • Scott, J.A.1    Scott, N.2    Gettinger, N.3    Quan Man Chow, L.4    Juergens, R.A.5    Borghaei, H.6
  • 117
    • 84863115998 scopus 로고    scopus 로고
    • Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape
    • Feb 15
    • Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 2012 Feb 15;72 (4):917-27.
    • (2012) Cancer Res , vol.72 , Issue.4 , pp. 917-927
    • Woo, S.R.1    Turnis, M.E.2    Goldberg, M.V.3    Bankoti, J.4    Selby, M.5    Nirschl, C.J.6
  • 118
    • 84856733781 scopus 로고    scopus 로고
    • Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization
    • Baitsch L, Legat A, Barba L, Fuertes Marraco SA, Rivals JP, Baumgaertner P, et al. Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization. PLoS One 2012;7(2):e30852.
    • (2012) PLoS One , vol.7 , Issue.2
    • Baitsch, L.1    Legat, A.2    Barba, L.3    Fuertes Marraco, S.A.4    Rivals, J.P.5    Baumgaertner, P.6
  • 119
    • 18344375283 scopus 로고    scopus 로고
    • Immunotherapy and chemotherapy - a practical partnership
    • May
    • Lake RA, Robinson BW. Immunotherapy and chemotherapy - a practical partnership. Nat Rev Cancer 2005 May;5(5):397-405.
    • (2005) Nat Rev Cancer , vol.5 , Issue.5 , pp. 397-405
    • Lake, R.A.1    Robinson, B.W.2
  • 120
    • 36849035139 scopus 로고    scopus 로고
    • Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies
    • Dec 15
    • O'Day SJ, Hamid O, Urba WJ. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer 2007 Dec 15;110(12):2614-27.
    • (2007) Cancer , vol.110 , Issue.12 , pp. 2614-2627
    • O'Day, S.J.1    Hamid, O.2    Urba, W.J.3
  • 121
    • 77953378992 scopus 로고    scopus 로고
    • CTLA-4 blockade: therapeutic potential in cancer treatments
    • Tarhini AA, Iqbal F. CTLA-4 blockade: therapeutic potential in cancer treatments. Onco Targets Ther 2010;3:15-25.
    • (2010) Onco Targets Ther , vol.3 , pp. 15-25
    • Tarhini, A.A.1    Iqbal, F.2
  • 122
    • 55949083407 scopus 로고    scopus 로고
    • Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment
    • Nov 10
    • Fong L, Small EJ. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol 2008 Nov 10;26(32):5275-83.
    • (2008) J Clin Oncol , vol.26 , Issue.32 , pp. 5275-5283
    • Fong, L.1    Small, E.J.2
  • 123
    • 34548191221 scopus 로고    scopus 로고
    • Update on anti-CTLA-4 antibodies in clinical trials
    • Aug
    • Langer LF, Clay TM, Morse MA. Update on anti-CTLA-4 antibodies in clinical trials. Expert Opin Biol Ther 2007 Aug;7(8):1245-56.
    • (2007) Expert Opin Biol Ther , vol.7 , Issue.8 , pp. 1245-1256
    • Langer, L.F.1    Clay, T.M.2    Morse, M.A.3
  • 124
    • 0032404099 scopus 로고    scopus 로고
    • Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice
    • Dec 1
    • Mokyr MB, Kalinichenko T, Gorelik L, Bluestone JA. Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice. Cancer Res 1998 Dec 1;58(23):5301-4.
    • (1998) Cancer Res , vol.58 , Issue.23 , pp. 5301-5304
    • Mokyr, M.B.1    Kalinichenko, T.2    Gorelik, L.3    Bluestone, J.A.4
  • 125
    • 84977741391 scopus 로고    scopus 로고
    • T-cell inflamed phenotype and PDL1 expression in malignant mesothelioma
    • Kindler Hedy Lee, Zuo Zhixiang, Khattri Arun, Keck Michaela K, Vigneswaran Wickii, Husain Aliya Noor, et al. T-cell inflamed phenotype and PDL1 expression in malignant mesothelioma. J Clin Oncol 2014;32(5s).
    • (2014) J Clin Oncol , vol.32 , Issue.5
    • Lee, K.H.1    Zhixiang, Z.2    Arun, K.3    Keck Michaela, K.4    Wickii, V.5    Noor, H.A.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.